age, comorbidity with diabetes mellitus (Livingston, Kalansooriya, Hartland, Ramachandran, & Heald, 2017) , various medications (Bhattacharya & Bhattacharya, 2015) and genetic polymorphisms (Jin et al., 2012) . Inadequate suppression of serum testosterone during ADT has been reported to impair the therapeutic effect by ADT (Oefelein & Cornum, 2000; . To date, only a few factors such as age (Pickles, Hamm, Morris, Schreiber, & Tyldesley, 2012) , obesity (Klotz et al., 2015; Smith, 2007) and genetic polymorphisms in SRD5A2 and GNRH2 (Shiota et al., 2018) have been identified to be associated with serum testosterone during ADT. However, the status of serum testosterone level among men with prostate cancer before or during ADT remains unknown although serum testosterone level has been suggested to be elevated in healthy men with cigarette smoking (Zhao, Leung, Lin, & Schooling, 2016) . In this study, we aimed to reveal the impact of smoking status on serum testosterone level before or during ADT, and the prognosis among men with metastatic prostate cancer.
| PATIENTS AND ME THODS

| Patients
Seventy-one Japanese patients treated with ADT for metastatic prostate cancer at Kyushu University Hospital (Fukuoka, Japan) between 1999 and 2013, whose serum testosterone level before ADT (n = 32, group 1) or during ADT (n = 62, group 2) are available, were retrospectively included. Twenty-three cases were included in both groups. This study was performed in accordance with the principles described in the Declaration of Helsinki and the Ethical Guidelines imaging and bone scan (Sobin & Wittekind, 1997) . Men who were cigarette smokers at the time of prostate cancer diagnosis were defined as current smokers. Body-mass index (kg/m 2 ) was calculated for each patient based on weight and height recorded prior to therapy. All patients were primarily treated by ADT with surgical castration or medical castration using a luteinising hormone-releasing hormone agonist (goserelin acetate or leuprorelin acetate) with or without an antiandrogen agent (bicalutamide, flutamide, or chlormadinone acetate) while patient was treated with neither up-front chemotherapy nor abiraterone. Progressive disease was defined as an increase in serum prostate-specific antigen (PSA) levels of >2 ng/ ml and a 25% increase over the nadir, the appearance of a new lesion or the progression of known lesions classified according to the Response Evaluation Criteria in Solid Tumors (Scher et al., 2008) .
| Measurement of serum testosterone level
Patient blood was obtained between 08:00 a.m. and 10:00 a.m., and serum testosterone levels were immediately measured by electrochemiluminescence immunoassay. Serum testosterone levels before ADT were measured once before an initiation of ADT .
Serum testosterone levels during ADT were measured at median of two times (range, 1-5 times) on the physician's judgement to confirm that serum testosterone was suppressed under castration level, and the mean value was employed as a representative value (Shiota et al., 2018) .
| Statistical analysis
All statistical analyses were performed using JMP13 software (SAS Levels of statistical significance were set at p < 0.05.
| RE SULTS
In group 1, serum testosterone levels before ADT among 32 men with metastatic prostate cancer were investigated. Clinicopathological characteristics including age and body mass index were compara- Figure 1b) . Serum testosterone levels during ADT were comparable between never smokers 
| D ISCUSS I ON
It has been shown that serum testosterone level is higher in cigarette smokers, in a meta-analysis of observational studies (Zhao et al., 2016) . Stopping or reducing cigarette smoking has been reported to decrease serum testosterone level in men, suggesting cigarette smoking is a cause of increased serum testosterone level (Trummer, Habermann, Haas, & Pummer, 2002) . For the first time, to our knowledge, the present study has shown higher serum testosterone in current smokers with metastatic prostate cancer. Intriguingly, less conversion of testosterone into oestrogen due to inhibition of aromatase by nicotine and cotinine (Barbieri, Gochberg, & Ryan, 1986 ) and low body fat in smokers (Chouinard et al., 2008) , and less androgen disposal due to UDP-glucuronidase inhibition by nicotine (Chen et al., 2010; Chouinard et al., 2008) have been suggested as possible mechanism of increased serum testosterone level in smokers. Thus, the inhibitory effect of testosterone degradation may cause higher serum testosterone level in smokers, although cigarette smoking may have a stimulatory effect on testosterone production.
As cigarette smoking can increase serum testosterone level, impaired suppression of serum testosterone in ADT by cigarette smoking may result in an inadequate therapeutic effect of ADT. However, the present study suggested successful suppression of serum TA B L E 2 Patient characteristics in group 2 testosterone level even in current smokers. Consistently, at least in the present study, cigarette smoking did not spoil the antitumor outcomes of ADT even when adjusted for serum testosterone levels before or during ADT However, recent meta-analysis showed worse prognosis in current smokers (Carter et al., 2015) while high serum testosterone before ADT was shown to be associated with better prognosis (Chodak et al., 1991; Shiota et al., 2015) . Therefore, the serum testosterone level in current smokers needs to be interpreted with caution, to avoid optimism over a high serum testosterone level in current smokers.
The present study has several limitations. The study design is retrospective, and the number in each cohort, especially the number of smokers was relatively small which lead to insufficient statistical power. In addition, the timing of serum testosterone measurement was varied, samples before and during ADT was not paired, and mass spectrometry suitable to measure low levels of testosterone was not utilised. As well, only serum testosterone level was investigated, whereas other androgen levels in serum and prostate tissue may be more suitable for evaluating androgen milieu. Further exploratory and validation studies on androgen milieu with cigarette smoking are required. Also, detailed data on the amount and duration of smoking are lacking.
The present study showed higher serum testosterone levels before ADT, but comparable serum testosterone levels during ADT among current smokers with metastatic prostate cancer although these findings should be validated in future due to limited statistical power in this study. The results suggest adequate pharmacological effect of ADT even in current smokers. However, the serum testosterone level in current smokers must be interpreted with caution, not to be optimistic over a high serum testosterone level in current smokers. Group Japan for editorial assistance.
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